MENU
ARAY
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Accuray (ARAY) Earnings Date & Reports

Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives... Show more

A.I. Advisor
published Earnings

ARAY is expected to report earnings to rise 250.00% to -7 cents per share on January 27

Accuray ARAY Stock Earnings Reports
Q4'26
Est.
$-0.07
Q2'26
Beat
by $0.01
Q1'26
Missed
by $0.07
Q4'25
Est.
$-0.11
Q3'25
Missed
by $0.13
The last earnings report on August 19 showed earnings per share of -1 cents, beating the estimate of -2 cents. With 80.62K shares outstanding, the current market capitalization sits at 13.14M.
A.I.Advisor
Nov 04, 2026

Accuray Incorporated (ARAY) First Quarter Fiscal 2027 Earnings Recap: Service Strength Meets Slower Product Orders

Key Takeaways

  • Accuray reported first quarter fiscal 2027 net revenue of $86.5 million, down 8% year over year, as product revenue continued to face pressure.
  • Service revenue rose 4% to $59.2 million, supported by a growing installed base and pricing actions.
  • Net income was $10.1 million, or $0.07 per diluted share, driven largely by a $59.6 million non-cash gain on debt extinguishment, partially offset by a $35.4 million goodwill impairment.
  • Excluding those items, the company posted a net loss of $14.0 million, or $0.10 per diluted share, an improvement from the $0.18 loss a year earlier.
  • Gross product orders fell to $19.8 million from $39.6 million, producing a book-to-bill ratio of 0.7, while order backlog declined roughly 31% to $272.0 million.
  • The company continues not to provide formal revenue or Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) guidance for fiscal 2027.
  • For more information about ARAY's Major News, Today's Price Move, Price Targets, and Forecast, explore these pages for a deeper look at the stock.
  • Discover Trending AI Robots to see the AI-driven trading strategies currently gaining momentum in the market.

Earnings Context and Why It Matters

Accuray's first quarter fiscal 2027 report lands at a pivotal moment in the radiation therapy company's transformation. After a fiscal 2026 marked by restructuring, cost reductions, and a financing transaction with TCW, investors are watching whether the company can convert its operational progress into renewed product demand. The quarter highlights a widening gap between a resilient, high-margin service business and a product segment pressured by geopolitical tensions and softness in China. With order volumes and backlog under scrutiny, this report offers a key read on whether Accuray's cost discipline and improved service economics can offset persistent demand headwinds and stabilize its financial footing.

Reported Results

Accuray reported total net revenue of $86.5 million for the first quarter of fiscal 2027, down $7.4 million, or 8%, from the prior-year period, and down 7% on a constant currency basis. This came in below the consensus estimate of roughly $95.8 million.

Service revenue grew 4% year over year to $59.2 million, up 5% on a constant currency basis, driven by pricing actions and growth in the global installed base. Product revenue declined to $27.3 million from $37.2 million, reflecting geopolitical factors and market issues in China.

Net income was $10.1 million, or $0.07 per diluted share, a figure heavily influenced by a $59.6 million non-cash gain on debt extinguishment tied to the July 2026 financing transaction and a $35.4 million non-cash goodwill impairment charge. Excluding both items, the company reported a net loss of $14.0 million, or $0.10 per diluted share, compared with a net loss of $0.18 per diluted share in the prior-year quarter. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) improved to $2.5 million from a negative $4.1 million a year earlier.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Accuray, it offers a structured way to surface opportunities that match specific criteria.

Market Reaction and Investor Sentiment

Investor sentiment around Accuray has remained cautious, with shares under significant pressure over the past year as product revenue and order trends deteriorated. While the reported headline EPS of $0.07 exceeded the consensus estimate of a $0.07 loss, that beat was driven by non-cash, one-time items rather than core operating performance. The revenue miss and the sharp decline in gross product orders are likely to weigh more heavily on how the market interprets the quarter. The 0.7 book-to-bill ratio and a backlog roughly 31% lower than a year ago signal weaker near-term demand visibility, reinforcing the cautious tone that has defined the stock's recent trading.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors should focus first on whether product orders and revenue can stabilize. Gross product orders were cut roughly in half year over year, and the book-to-bill ratio of 0.7 indicates the company is consuming backlog faster than it is replenishing it. A sustained recovery in orders, particularly outside China, will be central to restoring revenue growth.

Second, watch the trajectory of the services business. With an installed base now exceeding 1,100 systems and more than $230 million in recurring annual revenue, service growth and margin expansion provide a more durable foundation. Management reported a 410-basis-point improvement in service gross margin during the quarter, and continued progress here could support profitability even as product revenue lags.

Third, monitor geopolitical and tariff developments, especially in China and the Middle East, which have constrained demand and contributed to management's decision not to provide formal fiscal 2027 guidance. Finally, keep an eye on the balance sheet. The completed TCW financing steps, including the $15 million cash investment and the exchange of $40 million of term loan debt for convertible preferred equity, are intended to reduce leverage and improve liquidity, giving the company greater flexibility to execute its turnaround.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations